Vimpat
lacosamide
Table of contents
Overview
Vimpat is a medicine used on its own or as an add-on to other epilepsy medicines in the treatment of partial-onset seizures (epileptic fits starting in one specific part of the brain) with or without secondary generalisation (where the abnormal electrical activity spreads through the brain) in patients with epilepsy aged 24 years and older.
Vimpat can also be used as add-on to other epilepsy medicines in the treatment of primary generalised tonic-clonic seizures (major fits, including loss of consciousness) in patients from 4 years of age with idiopathic generalised epilepsy (the type of epilepsy that is thought to have a genetic cause).
Vimpat contains the active substance lacosamide.
-
List item
Vimpat : EPAR - Medicine overview (PDF/126.48 KB)
First published: 17/09/2008
Last updated: 25/03/2022
EMA/129643/2022 -
-
List item
Vimpat : EPAR - Risk Management Plan (PDF/5.17 MB)
First published: 05/09/2019
Last updated: 08/12/2022
Authorisation details
Product details | |
---|---|
Name |
Vimpat
|
Agency product number |
EMEA/H/C/000863
|
Active substance |
lacosamide
|
International non-proprietary name (INN) or common name |
lacosamide
|
Therapeutic area (MeSH) |
Epilepsy
|
Anatomical therapeutic chemical (ATC) code |
N03AX18
|
Publication details | |
---|---|
Marketing-authorisation holder |
UCB Pharma SA
|
Revision |
44
|
Date of issue of marketing authorisation valid throughout the European Union |
29/08/2008
|
Contact address |
Allée de la Recherche 60
BE-1070 Brussels Belgium |
Product information
12/10/2022 Vimpat - EMEA/H/C/000863 - N/0098
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Antiepileptics
Therapeutic indication
Vimpat is indicated as monotherapy and adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy.
Assessment history
News
-
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 January 202228/01/2022
-
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 October 202016/10/2020
-
21/07/2017
-
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 7-10 November 201611/11/2016
-
23/09/2011